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Siunmary: A sandwich enzyme linked immunosorbent assay (ELISA) for apolipoprotein C-III was developed.
Anti apolipoprotein C-III immunoglobulins were used both for coating of microtitre plates and for the
preparation of an anti apolipoprotein C-III horse-radish peroxidase conjugate.
Under optimized assay conditions, the sensitivity lies around 0.3 ng apolipoprotein C-III with a working
ränge of l to 6 ng. Standard curves are parallel for purified apolipoprotein C-III, for untreated plasma and
for lipoprotein fractions. Delipidation did not affect the content of apolipoprotein C-III in plasma. The assay
was evaluated by comparison with an immunonephelometric assay for apolipoprotein C-III, yielding a
correlation coefficient of 0.982 (n = 79). The mean intra- and interassay CV for the whole working ränge of
the assay were 3.6% and 4.2% respectively.
Enzyme linked immunosorbent assay (ELISA) für menschliches Apolipoprotein C-III
Zusammenfassung: Ein sandwich enzyme linked immunosorbent assay (ELISA) für Apolipoprotein C-III
wurde entwickelt. Für die Beschichtung von Mikrotiterplatten sowie die Herstellung eines anti-Apoliprotein
C-III-Meerrettichperoxidase-Konjugats wurden anti^Apolipoprotein C-III-Immunglobuline benutzt.
Unter optimierten Bedingungen beträgt die Empfindlichkeit des Bestimmungsverfahrens etwa 0,3 ng Apolipo-
protein C-III bei einem Einsatzbereich von l —6ng. Die Standardkurven für gereinigtes Apolipoprotein C-
III, unbehandeltes Plasma und Lipoproteinfraktionen verlaufen parallel. Die Lipidabtrennung beeinflußte
den Gehalt von Apolipoprotein C-III im Plasma nicht. Das Bestimmungsverfahren wurde durch Vergleich
mit einer immunnephelometrischen Methode zur Bestimmung Von Apolipoprotein C-III geprüft; der
Korrelationskoeffizient betrug 0*982 (n = 79). Die mittleren Variationskoeffizienten betrugen innerhalb der
Serie 3,6% und von Tag zu Tag 4,2%.
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Most studies have focused on the major apo- Immunological assays have been developed mainly
lipoproteins of HDL (apojipoproteins A-I and A-II) for the apolipoproteins A-I, A-II and B proteins
and LDL (apolipoprotein B). by a variety of techniques (7, 8). Quantitation of
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apolipoprotcin C-III by radioimmunoassay (RIA) (9,
10), clcctroimmunodiffusion (EID) (l 1), a competitive
enzyme linked immunosorbent assay (ELISA) (12)
and an immunonephelometric assay (INA) (13) have
been previously reported.
This report describes the technical optimization and
the validation of a Sandwich enzyme linked im-
munosorbent assay (ELISA), which was developed
for the measurement of human apolipoprotein C-III
in plasma and in lipoprotein fractions. Results are
evaluated by comparison with other techniques, de-
scribed previously.
Material and Methods
Isolation of apuliprotcins and production of antisera
The thrce apolipoprotcin C-III isoforras (i.e. apolipoproteins
C-1110, C-III, and C-HI2) were isolated from human
apolipoprotcins of Vcry Low Density Lipoproteins by a combin-
ation of gcl Filtration on a Sephacryl S 200 column and ion-
exchangc chromatography on a DEAE-cellulose column, s
described previously (13). The homogeneity of the
apolipoprotein C-III preparation, used s primary Standard and
immunogcn, was checked by electrophoresis on polyacrylamide
gcls, containing cither 8 mol/1 urca (14) or l g/l sodium dodecyl
sulphate (15), by immunodiffusion with antisera against
apolipoprotein A-I, A-II, B, C-III, E and albumin, and by
amino acid analysis, based on the composition of purified
apolipoprotein C-III (16).
Apolipoprotein A-I and apolipoprotein A-II were purified from
apo High Density Lipoproteins by ion exchange chro-
matography (17, 18). Watcr soluble apolipoprotein B was pre-
pared from Low Density Lipoproteins (d = 1.030-1.050 kg/l)
s described by Cardin et al. (19) and apolipoprotein E were
isolated from apolipoproteins of Very Low Density Lipoproteins
by high performance liquid chromatography using an Ultro-
Pak TSK-G 3000 SW column (LKB, Broma, Sweden) (20, 21).
The antiscra to these purified apolipoproteins were raised in
rabbits s prcviously described (13, 18, 22, 23).
Preparation of the coater and the enzyme-antibody conjugate
An apolipoprotein C-III affmity column was prepared by
covalent linkage of 8 mg apolipoprotein C-III to l g CNBr-
activated Sepharosc 4 B (Pharmacia, Uppsala, Sweden) (24).
Anti human apolipoprotein C-III immunoglobulins were iso-
lated from a rabbit antiserum by affmity chromatography,
according to the Standard procedure, and were used both
for coating and for the preparation of an enzyme-antibody
conjugate. For this purpose 2 mg of horse-radish peroxidase
was covalently linked to 4mg purified anti-apolipoprotein
C-III immunoglobulin by the periodate coupling procedure
described by Nakane (25).
The immunoglobulins, used for coating, were stored at 4°C in
0.05 mol/1 sodium borate, 0.15 mol/1 NaCl, containing l g/i
NaN3, whilc the antibody-enzyme conjugate was stored in
aliquots at -20°C, mixed with an equal volume of glycerol
(26). This preparation was stable for at least six months, without
any loss of activity.
Buffer System
A sodium phosphate buffer 10mmol/l pH 7.4, containing
0.15 mol/1 NaCl was used throughout the whole procedure for
coating, incubations and washings. In addition the coating
buffer contained l g/l NaN3, whereas the assay buffer containcd
10 g/l bovine serum albumin (27). To reduce non-specific bind-
ing, the wash buffer contained 0.5 ml/l Tween 20 (26).
Coating of the solid phase
Purified anti-apolipoprotein C-III immunoglobulins (ΙΙΟμΙ) at
a concentration of 25 mg/1 were pipetted' into each well of a
polystyrene microtitre plate (Fiat Bottom micro ELISA plates,
129 B, Dynatech Lab Inc., Alexandria, Virginia, 22314), exclud-
ing the outer rows which tend to produce edge effects (28). The
plates were sealed (Sealing tape, Dynatech), and incubated for
3 h at 37°C before an overnight incubation at 4°C. The plates
were used either immediately or stored with the coater at 4°C
for a maximum of two weeks. Before use the plates were washed
three times with wash buffer and incubated one hour at room
temperature with the assay buffer, in order to block any residual
coupling sites with albumin (29). The plates were subsequently
washed three times and shaken dry.
Apolipoprotein C-III quantitation by Sandwich ELISA
Standard or plasma samples (ΙΟΟμΙ), representing 5000-fold
dilutions (Microlab 1000 dilutor, Hamilton, Bonaduz, Switzer-
land), were pipetted into the wells of a precoated microtitre
plate. The plates were covered and incubated at 37°C for 2 h.
The content of each well was aspirated and the plates were
washed five times. After 10000 dilution with assay buffer, the
affmity purified anti-apolipoprotein OIII peroxidase conjugate
(100 μΐ) was added to each well and plates were incubated for
2 h at 37 °C. The wells were subsequently emptied and washed
five times. The o-phenylenediamine hydrochloride Substrate
(Sigma chemical Co, St. Louis, MO 63178), at a concentration
of 3 g/l, was freshly prepared in a 0.01 mol/1 sodium-phosphate-
citr te buffer pH 5.6, containing 0.2 g/l H2O2. An aliquot of
this solution (ΙΟΟμΙ) was pipetted into each well at timed
intervals and left at roora temperature in the dark. After 30 min
the reaction was blocked by adding 100 μΐ of 2.5 mol/1 sulphuric
acid (Analytical Grade, Merck, Darmstadt, FRG). The de-
veloped colour was read within two hours on a Chfomo Scan
EIA Reader (Bio-Tech Instrument, Burlington, VT 05401) at
490 nm.
Calibration curves were obtained frorh the appropriate dilutions
of purified apolipoprotein QIII2, whose concentration was
assessed by amino acid analysis. This primary Standard was
solubilized in the sodium phosphate buffer, containing the
nonionic detergent Apovax (Ortho Diagnostics, Beerse,
Belgium) at a concentration of 0.1 g/l, then further diluted with
the ELISA assay-buffer. Sera from normolipidaeinic donors,
aliquoted and stored at -20°C, were used s a suitable
secondary Standard and control (7, 8). Standard curves were
obtained by plotting the absorbance at 490 nm s function of
the logarithm of the apolipoprotein C-III concentration.
Apolipoprotein C-III distribution in lipoprotein fractions
Lipoproteins were separated from l ml fresh disodium EDTA-
plasma (l g/l) by gel filtration on a Sepharose 6 BCL column
(1.6 χ 90cm), equilibrated with 2mmol/l Na3PO4, 0.2 mol/1
NaCl, l mmol/1 disodium EDTA and l g/l NaN3, pH 7.4 and
eluted at 9.2 ml/h. Apolipoprotein C-III was assayed in all
fractions by the ELISA procedure described above and
cholesterol was assayed enzymatically (30).
Results
Optimization of the assay conditions
Optimal coating concentration and conjugate dilution
were determined by using the chequerboard titration,
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described by Voller et aL (26). A good sensitivity,
together with a low zero-dose response were achieved,
using a coating concentration of 25 μ§ purified anti-
apolipoprotein C-III immunoglobulins per ml coating
buffer and a final antibody-peroxidase dilution of
10000 fold.
A second coating with albumin, to block any residual
binding sites on the polystyrene plates (29) decreased
the intra-assay CV by a factor two. This procedure,
in combination with the use of 0.5 ml Tween 20 per l
wash buffer, yielded a four-fold increase of the intra-
assay precision from 13.5% to 3.8%.
Standardiza on
As shown in figure l, the calibration curve constructed
with purified apolipoprotein C-III2 and with the
plasma obtained from a normolipidaemic subject and
from a subject with a severe Fredrickson type V
hyperlipoproteinaemia (triglycerides 47.25 g/l and
cholesterol 8.85 g/l) were identical. Delipidation of
the plasma samples (31) did not increase the
apolipoprotein C-III immunoreactivity, indicating
that all apolipoprotein G-III epitopes are accessible
to titration in native plasma.
The calibration curves, obtained with lipoprotein
fractions freshly isolated from plasma by sequential
ultracentrifugation, paralleled the Standard curve con-
structed with purified apolipoprotein C-III2 (fig. 2).
Identical curves were obtained after delipidation of
chylomicra, Very Low Density Lipoproteins and High
Density Lipoproteins.
3.0
2.5
2.0
o
< 1.5
1.0
0.5
0.0 0.5 1 25 5 10
Apolipoprotein C-ΠΙ [ng]
Fig. 1. Calibration curves for apolipoprotein C-III quantita-
tion by ELISA: purified apolipoprotein (x),
normolipidaemic plasma ($) (mean ± l SD),
normolipaemic delipidated plasma (O), plasma from a
Fredrickson type V patient native (Q) and delipidated
(O).
Sensitivity, precision and accuracy
The enzyme linked immunosorbent assay is sensitive
down to 0.3 ng apolipoprotein C-III with a working
r nge of l to 6 ng apolipoprotein C-III. Using a 5000
fold dilution, this r nge corresponds to apolipoprotein
C-III plasma concentrations fcetween 0.05 and 0.30
g/l.
3.0 ·
0.5 25 5 10 25
Protein [ng]
100 250
Fig. 2. Standard curves, constmcted with purified apolipoprotein C-III (x), chylomicra (Δ), VLDL (V) and HDL2 (A),
apolipoproteins A-I (O), A-II (Φ), B (D), E (+) and human albumin (E).
J. Clin. Cfaem. Clin. Biochem. / Vol. 23, 1985 / No. 2
66 Bury and Rosseneu: Enzyme linked immunosorbent assay for apolipoprotein C-III
The selecüvity of the ELISA for apolipoprotein C-
III was investigated by constructing calibration curves
with purified apolipoproteins A-I, A-II, B, C-III2, E
and human albumin. As shown in figure 2, the cross-
reactivity of these antigens with anti-apolipoprotein
C-III immunoglobulins, amounted to 1.02,0.00,0.51,
100.00, 0.56 and 0.00% respectively.
Five plasma samples, with low, intermediate and high
concentrations of apolipoprotein C-III, were änalysed
twenty times in the same assay and twice a week
during five weeks to calculate the assay precision. As
shown in tablel, the average intra- and inter-assay
CV amounted to 3.6% and 4.2% respeetively.
Tab. 1. Precision of the apolipoprotein C-III ELISA assay.
Apolipoprotein C-III
concentration
(g/I)
0.090
0.126
0.144
0.220
0.303
Intra-assay CV
(n = 20)
(%)
4.33
4.14
3.83
3.81
1.86
Inter-assay
(n = 10)
(%)
2.84
2.39
4.87
5.67
5.36
CV
In order to investigate the accuracy of the assay,
apolipoprotein C-III was assayed in 79 plasma
samples both by immunonephelometry (13) and by
the ELISA procedure described above. The regression
line between the two techniques (fig. 3) has a correl-
ation coefficient of 0.982 and is represented by the
equation y = 0.988x - 0.002. A paired t-test failed
to detect any significant difference (p < 0.05) between
the two immunoassays.
Apolipoprotein C-HI concentrations in human plasma
Table 2 summarizes the plasma concentrations of
apolipoprotein C-III in normal and hyper-
lipoproteinaemic subjects äs determined by the ELISA
procedure. The mean apolipoprotein C-III con-
centration in 34 normolipaemic subjects was 0.101 ±
0.03 g/l. Fredrickson type II a patients had only slightly
0.00 0.25 0.50 0.75
Apolipoprotein C-ffl (INA) [g/l]
Fig. 3. Correlation between the enzyme linked immunosorbent
assay (ELISA) and the immunonephelometric assay
(INA) for the quantitation of plasma apolipoprotein C-
III.
y = 0.988x - 0.002. r = 0.982. N = 79.
elevated apolipoprotein C-III levels, whereas all other
hyperlipoproteinaemic subjects had significantly
higher (p < 0.001) apolipoprotein C-III vahies than
normals and type Ila patients. The highest
apolipoprotein C-III concentratipns were observed in
Fredrickson type V hyperlipoproteinaemic patients.
Investigations on 76 patients with a wide ränge of
total plasma triglycerides (0.27^-47.25 g/l), and total
plasma cholesterol (l .02-8.85 g/l) showed that
apolipoprotein C-III plasma concentrations were
positively correlated with plasma triglycerides (r =
0.93) and total plasma cholesterol (r = 0.83).
Distribution of apolipoprotein
lipoprotein fractions
C-III among the
The apolipoprotein GJII profile was investigated in
3 normal and 3 severe Fredrickson type V subjects
Tab. 2. Concentrations of apolipoprotein C-III (mean ± SD) in plasma from normal and hyperlipoproteinaemic subjects.
Subjects
Phenotype
N .
I
Ha
Ilb
IV
V
number
34
2
17
14
6
6
Triglycerides
_/ig/1
0.73 + 0.29
22.90
1.05 ± 0.31
2.72 ± 1.06
3.88 + 1.63
21.08 ± 8.85
Cholesterol
/lg/l
1.97 ± 0.40
2.58
3.33 + 0.55
3.56 ± 0.60
2.49 ± 0.35
6.12 ± 1.47
Apolipoprotein C-III
_/|g/i
0.101 -f 0.031
0.311
0.168 ± 0.31
0.307 + 0.047
0.338 ± 0.081
0.716, ± 0.223
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äs described under methods. In the normolipaemic
subjects apolipoprotein C-III was distributed äs
follows: 15.4 ± 0.8% (mean ± SD) in the Very Low
Density Lipoproteins, 11.1 ± 0.6% in Low Density
Lipoproteins and 73.5 ± 2.9% in High Density
Lipoproteins. In the three Fredrickson type V patients
86.8 ± 4.9% of the apolipoprotein C-III was found
in the triglyceride-rich lipoproteins (i.e. chylomicra
and Very Low Density Lipoproteins) while High
Density Lipoproteins cholesterol contained only 5.6
± 1.7% apolipoprotein C-III (cf. fig. 4).
15 20 25 30 35
Tube number
Fig. 4. Apolipoprotein C-III profile in a normolipaemic sub-
ject (a) and a patient with a Fredrickson type V
hyperlipoproteinaemia (b). Fresh plasma (l ml) was sep-
arated on a Sepharose 6 B cplumn and apolipoprotein
C-III (0) and cholesterol (x) were measured in all
fractions.
Discussion
Several immunological assays have been described for
the measurement of human apolipoprotein C-III
(9 — 13) each of which has its own characteristics and
liinitations. For the electro-immunodiffusion assay
(EID) the seleetion of a primary Standard with the
same migration properties äs the unknown sample is
critical. The major limitation of laser nephelometric
assays is the sample turbidity. This is caused by
the presence of triglyceride-rich lipoproteins, and
necessitates sample delipidation prior to the assay
(13). Radioimmunoassay is the most sensitive tech-
nique: down to 0.8 ng apolipoprotein C-III (10).
However, it suffers from various major drawbacks,
including expensive counting equipment, unstable
reagents and biohazards, associated with the handling
of radioisotopes. These disadvantages can easily be
circumvented by replacing the isotope label by an
enzyme.
For this purpose a non-competitive enzyme linked
immunosorbent assay was developed for the meas-
urement of apolipoprotein C-III. The Sandwich type
assay was selected, äs both coater and conjugate
can be prepared from immunoglobulins with a high
stability i. e.: the anti-apolipoprotein C-III-peroxidase
conjugate was stable for at least 6 months, without
loss of activity.
Standard curves, constructed either with plasma äs a
secondary Standard or with lipoprotein fractions,
paralleled the calibration curves, constructed with
purified apolipoprotein C-III, which served äs the
primary Standard. In contrast with the electro-
iminunoassay described by Curry et al. (11), the
apolipoprotein C-III immunoreactivity was not en-
hanced by delipidation. Therefore, the ELISA assay
does not detect any difference in the exposure of the
apolipoprotein C-III epitopes, on the free or on the
lipid-boünd protein.
Compared with previously described techniques (CV:
6 — 13%), the use of affinity purified antibodies
yielded a high assay sensitivity (0.3 ng apolipoprotein
C- ) and Standard curves with a steep slope, together
with a high assay precision (CV: 4%).
The ELISA assay was evaluated by comparison with
an immunonephelometric assay for apolipoprotein
C-III, yielding a correlation coefficient of 0.982 (n =
79). Plasma apolipoprotein C-III and triglyceride
concentrations were well correlated (r = 0.93, n = 76)
äs shown by a 3-fold increase of apolipoprotein
C-III levels in patients with hypertriglyceridaemia
(Fredrickson types I, II b and IV), and by a 5 to 10-
fold increase in patients with a Fredrickson type V
hyperlipoproteinaemia äs compared to nor-
molipidaemic subjects.
Apolipoprotein C-III, which plays an important role
in triglyceride catabolism, is distributed among tri-
glyceride-rich lipoproteins and HDL. This dis-
tribution can easily be influenced by both
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endogeneous and exogeneous factors (32). Due to its
sensitivity and precision this ELISA assay is especially
suited to the study of apolipoprotein C-III profiles
after plasma lipoprotein Separation by either column
chromatography or gradient ultracentrifugation.
This was demonstrated on normolipaemic and hy-
pertriglyceridaemic plasma samples separated on a
Sepharose 6 B column. In agreement with previous
reports (9, 11-13), the hypertriglyceridaemic state is
attented by a higher amount of apolipoprotein C-III in
the triglyceride-rich lipoprotein fractions, suggesting
that the apolipoprotein C-III profile could become a
useful marker of triglyceride metabolism.
The characterization of the apolipoprotein C-III con-
tent and distribution in plasma should provide a
better insight in to the function of this apolipoprotein
in lipoprotein metabolism. f
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